Economic burden of melanoma in the elderly population: Population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)-medicare data

Archives of Dermatology

Volumn 146, Issue 3, 2010, Pages 249-256

  Seidler, Anne M ^a   Pennie, Michelle L ^a   Veledar, Emir ^a   Culler, Steven D ^b   Chen, Suephy C ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ECONOMIC ASPECT; FEMALE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MELANOMA; PRIORITY JOURNAL; UNITED STATES;

AGE FACTORS; AGED; COST OF ILLNESS; COSTS AND COST ANALYSIS; HUMANS; INCIDENCE; MEDICARE; MELANOMA; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROGNOSIS; SEER PROGRAM; SKIN NEOPLASMS; TIME FACTORS; UNITED STATES;

EID: 77949379989     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.389     Document Type: Article

References (21)

1. American Cancer Society. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Marks R. An overview of skin cancers: incidence and causation. Cancer. 1995;75 (2)(suppl):607-612.
3. Almahroos M, Kurban AK. Ultraviolet carcinogenesis in nonmelanoma skin cancer, part II: review and update on epidemiologic correlations. Skinmed. 2004;3(3):132-139.
4. Geller AC, Miller DR, Annas GD, Demierre M-F, Gilchrest BA, Koh HK. Melanoma incidence and mortality among US whites, 1969-1999. JAMA. 2002;288(14):1719-1720.
5. Geller AC, Miller DR, Swetter SM, Demierre M-F, Gilchrest BA. A call for the development and implementation of a targeted national melanoma screening program. Arch Dermatol. 2006;142(4):504-507.
6. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999;37(12):1249-1259.
7. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEERMedicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8):(suppl 8):IV-3-IV-18.
8. Pennie ML, Soon SL, Risser JB, Veledar E, Culler SD, Chen SC. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. Arch Dermatol. 2007;143(4):488-494.
9. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19(16):3635-3648.
10. American Joint Committee on Cancer. Malignant melanoma of the skin. In: Manual for Staging of Cancer. Philadelphia, PA: JB Lippincott; 1997:163-167.
11. Fader DJ, Wise CG, Normolle DP, Johnson TM. The multidisciplinary melanoma clinic: a cost outcomes analysis of specialty care. J Am Acad Dermatol. 1998; 38(5, pt 1):742-751.
12. Huang CL, Provost N, Marghoob AA, Kopf AW, Levin L, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol. 1998;39(3):451-463.
13. Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002;20(1):307-316.
14. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;46(1):5-27.
15. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER cancer statistics review, 1975-2004. National Cancer Institute. http://seer.cancer.gov/csr/1975- 2004/. Accessed May 30, 2007.
16. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1998;38(5, pt 1):669-680.
17. Health Care Financing Administration, Bureau of Quality Control. Carrier Reasonable Charge and Denial Activity Report January-March 1985. Washington, DC: US Dept of Health and Human Services; 1985.
18. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524-3530.
19. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995; 33(8):828-841.
20. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19(5):1455-1461.
21. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? insight from Surveillance, Epidemiology, and End Results-Medicare. J Clin Oncol. 2001;19(17):3712-3718.